25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Daehan New Pharm Co. Ltd
Buy, Hold or Sell?

Let's analyze Daehan New Pharm Co. Ltd together

I guess you are interested in Daehan New Pharm Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Daehan New Pharm Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Daehan New Pharm Co. Ltd

I send you an email if I find something interesting about Daehan New Pharm Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Daehan New Pharm Co. Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Daehan New Pharm Co. Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.14
When do you have the money?
1 year
How often do you get paid?
33.3%

What is your share worth?

Current worth
₩8,664.96
Expected worth in 1 year
₩9,420.64
How sure are you?
74.1%

+ What do you gain per year?

Total Gains per Share
₩955.68
Return On Investment
13.8%

For what price can you sell your share?

Current Price per Share
₩6,950.00
Expected price per share
₩6,180 - ₩7,600
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Daehan New Pharm Co. Ltd (5 min.)




Live pricePrice per Share (EOD)
₩6,950.00
Intrinsic Value Per Share
₩-56,992.44 - ₩-68,822.84
Total Value Per Share
₩-48,327.49 - ₩-60,157.88

2.2. Growth of Daehan New Pharm Co. Ltd (5 min.)




Is Daehan New Pharm Co. Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$85.1m$73.6m$7.6m9.4%

How much money is Daehan New Pharm Co. Ltd making?

Current yearPrevious yearGrowGrow %
Making money$2.1m$3.5m-$1.3m-62.2%
Net Profit Margin6.2%9.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Daehan New Pharm Co. Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Daehan New Pharm Co. Ltd?

Welcome investor! Daehan New Pharm Co. Ltd's management wants to use your money to grow the business. In return you get a share of Daehan New Pharm Co. Ltd.

First you should know what it really means to hold a share of Daehan New Pharm Co. Ltd. And how you can make/lose money.

Speculation

The Price per Share of Daehan New Pharm Co. Ltd is ₩6,950. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Daehan New Pharm Co. Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Daehan New Pharm Co. Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩8,664.96. Based on the TTM, the Book Value Change Per Share is ₩188.92 per quarter. Based on the YOY, the Book Value Change Per Share is ₩300.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩50.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Daehan New Pharm Co. Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.280.0%0.160.0%0.250.0%0.150.0%0.080.0%
Usd Book Value Change Per Share0.180.0%0.130.0%0.210.0%0.190.0%0.220.0%
Usd Dividend Per Share0.000.0%0.030.0%0.060.0%0.030.0%0.020.0%
Usd Total Gains Per Share0.180.0%0.170.0%0.270.0%0.210.0%0.240.0%
Usd Price Per Share5.34-5.92-6.16-7.09-7.67-
Price to Earnings Ratio4.78-1.73-6.43-4.79-5.11-
Price-to-Total Gains Ratio29.30-10.30-61.65-21.01-19.58-
Price to Book Ratio0.88-1.02-1.18-1.91-2.39-
Price-to-Total Gains Ratio29.30-10.30-61.65-21.01-19.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.865
Number of shares205
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.03
Usd Book Value Change Per Share0.130.19
Usd Total Gains Per Share0.170.21
Gains per Quarter (205 shares)34.2943.14
Gains per Year (205 shares)137.14172.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12910812721152163
25721726441304336
38632540162456509
411543453883608682
5143542675103760855
61726518121249111028
720175994914510631201
8230868108616512151374
9258976122318613671547
102871084136020715191720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%17.03.00.085.0%21.06.00.077.8%21.06.00.077.8%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%15.05.00.075.0%19.07.01.070.4%19.07.01.070.4%
Dividend per Share2.00.02.050.0%8.00.04.066.7%8.00.012.040.0%9.00.018.033.3%9.00.018.033.3%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%16.04.00.080.0%20.06.01.074.1%20.06.01.074.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Daehan New Pharm Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--260.438188.920+38%300.223-13%264.642-2%320.924-19%
Book Value Per Share--8664.9608276.400+5%7499.560+16%6003.065+44%5367.599+61%
Current Ratio--1.5601.634-4%1.738-10%1.571-1%1.436+9%
Debt To Asset Ratio--0.3840.378+2%0.382+1%0.465-17%0.499-23%
Debt To Equity Ratio--0.6230.607+3%0.619+1%0.921-32%1.068-42%
Dividend Per Share---50.000-100%90.000-100%36.000-100%28.518-100%
Enterprise Value--31290334150.00057446661677.500-46%78960501915.000-60%89148112410.000-65%95242524804.444-67%
Eps--398.950222.766+79%361.278+10%221.045+80%115.540+245%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.1440.287-50%0.383-62%0.526-73%infnan%
Free Cash Flow Per Share---986.302-198.445-80%291.274-439%94.708-1141%102.196-1065%
Free Cash Flow To Equity Per Share---986.302-225.847-77%-21.254-98%-34.717-96%-4.617-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.963+4%
Intrinsic Value_10Y_max---68822.844--------
Intrinsic Value_10Y_min---56992.445--------
Intrinsic Value_1Y_max---704.544--------
Intrinsic Value_1Y_min---688.393--------
Intrinsic Value_3Y_max---6835.883--------
Intrinsic Value_3Y_min---6430.832--------
Intrinsic Value_5Y_max---18656.537--------
Intrinsic Value_5Y_min---16910.359--------
Market Cap97545335000.000-10%107089339000.000118598285000.000-10%123545728250.000-13%142254783150.000-25%153691733259.259-30%
Net Profit Margin--0.1030.062+67%0.098+6%0.065+59%0.025+321%
Operating Margin----0%-0%0.050-100%0.043-100%
Operating Ratio--1.3981.448-3%1.197+17%0.825+69%0.935+50%
Pb Ratio0.802-10%0.8811.025-14%1.176-25%1.913-54%2.392-63%
Pe Ratio4.355-10%4.7811.731+176%6.428-26%4.7910%5.107-6%
Price Per Share6950.000-10%7630.0008450.000-10%8802.500-13%10135.500-25%10950.370-30%
Price To Free Cash Flow Ratio-1.762+9%-1.9341.742-211%8.634-122%7.412-126%11.407-117%
Price To Total Gains Ratio26.686-10%29.29710.302+184%61.649-52%21.006+39%19.580+50%
Quick Ratio--0.6000.788-24%1.102-46%1.065-44%0.970-38%
Return On Assets--0.0280.016+76%0.030-5%0.019+48%0.008+264%
Return On Equity--0.0460.026+78%0.048-5%0.033+39%0.007+534%
Total Gains Per Share--260.438238.920+9%390.223-33%300.642-13%349.443-25%
Usd Book Value--85130716.77681313228.043+5%73681004.919+16%58978376.095+44%52735107.537+61%
Usd Book Value Change Per Share--0.1820.132+38%0.210-13%0.185-2%0.225-19%
Usd Book Value Per Share--6.0655.793+5%5.250+16%4.202+44%3.757+61%
Usd Dividend Per Share---0.035-100%0.063-100%0.025-100%0.020-100%
Usd Enterprise Value--21903233.90540212663.174-46%55272351.341-60%62403678.687-65%66669767.363-67%
Usd Eps--0.2790.156+79%0.253+10%0.155+80%0.081+245%
Usd Free Cash Flow---9690130.506-1949667.085-80%2861680.092-439%930475.589-1141%1004042.658-1065%
Usd Free Cash Flow Per Share---0.690-0.139-80%0.204-439%0.066-1141%0.072-1065%
Usd Free Cash Flow To Equity Per Share---0.690-0.158-77%-0.015-98%-0.024-96%-0.003-100%
Usd Market Cap68281734.500-10%74962537.30083018799.500-10%86482009.775-13%99578348.205-25%107584213.281-30%
Usd Price Per Share4.865-10%5.3415.915-10%6.162-13%7.095-25%7.665-30%
Usd Profit--3919568.6112188610.519+79%3549449.521+10%2162813.026+81%1039134.271+277%
Usd Revenue--37896408.67635388447.103+7%36083289.480+5%31075877.295+22%27952240.229+36%
Usd Total Gains Per Share--0.1820.167+9%0.273-33%0.210-13%0.245-25%
 EOD+3 -5MRQTTM+19 -18YOY+12 -255Y+17 -2110Y+19 -19

3.3 Fundamental Score

Let's check the fundamental score of Daehan New Pharm Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.355
Price to Book Ratio (EOD)Between0-10.802
Net Profit Margin (MRQ)Greater than00.103
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.600
Current Ratio (MRQ)Greater than11.560
Debt to Asset Ratio (MRQ)Less than10.384
Debt to Equity Ratio (MRQ)Less than10.623
Return on Equity (MRQ)Greater than0.150.046
Return on Assets (MRQ)Greater than0.050.028
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Daehan New Pharm Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.768
Ma 20Greater thanMa 506,932.500
Ma 50Greater thanMa 1007,369.200
Ma 100Greater thanMa 2008,117.600
OpenGreater thanClose7,010.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Daehan New Pharm Co. Ltd

Daehan New Pharm Co., Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers human medicine products, such as circulatory and endocrine system drugs; animal medicines; biopharmaceuticals, including biomedicine serums; export medicine which comprises of antibiotics, antineoplastics, and others; health functional food, as well as vitamins; and beauty and medical devices. The company was formerly known as Daehan Shinyak Co., Ltd. and changed its name to Daehan New Pharm Co., Ltd in April 2001. Daehan New Pharm Co., Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 18:17:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Daehan New Pharm Co. Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 10.3% means that ₩0.10 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 10.3%. The company is making a huge profit. +2
  • The TTM is 6.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ10.3%TTM6.2%+4.1%
TTM6.2%YOY9.8%-3.6%
TTM6.2%5Y6.5%-0.3%
5Y6.5%10Y2.5%+4.0%
4.3.1.2. Return on Assets

Shows how efficient Daehan New Pharm Co. Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.8% Return on Assets means that Daehan New Pharm Co. Ltd generated ₩0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 2.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.8%TTM1.6%+1.2%
TTM1.6%YOY3.0%-1.4%
TTM1.6%5Y1.9%-0.3%
5Y1.9%10Y0.8%+1.1%
4.3.1.3. Return on Equity

Shows how efficient Daehan New Pharm Co. Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.6% Return on Equity means Daehan New Pharm Co. Ltd generated ₩0.05 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 4.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.6%TTM2.6%+2.0%
TTM2.6%YOY4.8%-2.3%
TTM2.6%5Y3.3%-0.7%
5Y3.3%10Y0.7%+2.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Daehan New Pharm Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Daehan New Pharm Co. Ltd is operating .

  • Measures how much profit Daehan New Pharm Co. Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y5.0%-5.0%
5Y5.0%10Y4.3%+0.6%
4.3.2.2. Operating Ratio

Measures how efficient Daehan New Pharm Co. Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.40 means that the operating costs are ₩1.40 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 1.398. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.448. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.398TTM1.448-0.050
TTM1.448YOY1.197+0.251
TTM1.4485Y0.825+0.623
5Y0.82510Y0.935-0.110
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Daehan New Pharm Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Daehan New Pharm Co. Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.56 means the company has ₩1.56 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 1.560. The company is able to pay all its short-term debts. +1
  • The TTM is 1.634. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.560TTM1.634-0.073
TTM1.634YOY1.738-0.104
TTM1.6345Y1.571+0.063
5Y1.57110Y1.436+0.134
4.4.3.2. Quick Ratio

Measures if Daehan New Pharm Co. Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.60 means the company can pay off ₩0.60 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 0.600. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.788. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.600TTM0.788-0.188
TTM0.788YOY1.102-0.315
TTM0.7885Y1.065-0.278
5Y1.06510Y0.970+0.095
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Daehan New Pharm Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Daehan New Pharm Co. Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Daehan New Pharm Co. Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.38 means that Daehan New Pharm Co. Ltd assets are financed with 38.4% credit (debt) and the remaining percentage (100% - 38.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 0.384. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.378. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.384TTM0.378+0.006
TTM0.378YOY0.382-0.004
TTM0.3785Y0.465-0.088
5Y0.46510Y0.499-0.034
4.5.4.2. Debt to Equity Ratio

Measures if Daehan New Pharm Co. Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 62.3% means that company has ₩0.62 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Daehan New Pharm Co. Ltd:

  • The MRQ is 0.623. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.607. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.623TTM0.607+0.016
TTM0.607YOY0.619-0.012
TTM0.6075Y0.921-0.314
5Y0.92110Y1.068-0.147
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Daehan New Pharm Co. Ltd generates.

  • Above 15 is considered overpriced but always compare Daehan New Pharm Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 4.78 means the investor is paying ₩4.78 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Daehan New Pharm Co. Ltd:

  • The EOD is 4.355. Based on the earnings, the company is cheap. +2
  • The MRQ is 4.781. Based on the earnings, the company is cheap. +2
  • The TTM is 1.731. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.355MRQ4.781-0.426
MRQ4.781TTM1.731+3.050
TTM1.731YOY6.428-4.697
TTM1.7315Y4.791-3.060
5Y4.79110Y5.107-0.316
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Daehan New Pharm Co. Ltd:

  • The EOD is -1.762. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.934. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 1.742. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-1.762MRQ-1.934+0.172
MRQ-1.934TTM1.742-3.676
TTM1.742YOY8.634-6.892
TTM1.7425Y7.412-5.670
5Y7.41210Y11.407-3.995
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Daehan New Pharm Co. Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.88 means the investor is paying ₩0.88 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Daehan New Pharm Co. Ltd:

  • The EOD is 0.802. Based on the equity, the company is cheap. +2
  • The MRQ is 0.881. Based on the equity, the company is cheap. +2
  • The TTM is 1.025. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.802MRQ0.881-0.078
MRQ0.881TTM1.025-0.144
TTM1.025YOY1.176-0.152
TTM1.0255Y1.913-0.889
5Y1.91310Y2.392-0.479
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets197,414,315
Total Liabilities75,799,005
Total Stockholder Equity121,615,310
 As reported
Total Liabilities 75,799,005
Total Stockholder Equity+ 121,615,310
Total Assets = 197,414,315

Assets

Total Assets197,414,315
Total Current Assets99,421,009
Long-term Assets97,993,306
Total Current Assets
Cash And Cash Equivalents 20,105,850
Short-term Investments 1,820,000
Net Receivables 36,389,449
Inventory 33,609,701
Total Current Assets  (as reported)99,421,009
Total Current Assets  (calculated)91,925,001
+/- 7,496,008
Long-term Assets
Property Plant Equipment 68,689,992
Intangible Assets 1,186,657
Long-term Assets Other 354,303
Long-term Assets  (as reported)97,993,306
Long-term Assets  (calculated)70,230,952
+/- 27,762,354

Liabilities & Shareholders' Equity

Total Current Liabilities63,711,888
Long-term Liabilities12,087,117
Total Stockholder Equity121,615,310
Total Current Liabilities
Short Long Term Debt 35,714,114
Accounts payable 13,083,623
Other Current Liabilities 0
Total Current Liabilities  (as reported)63,711,888
Total Current Liabilities  (calculated)48,797,737
+/- 14,914,152
Long-term Liabilities
Long term Debt 7,080,000
Capital Lease Obligations Min Short Term Debt1,046,240
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)12,087,117
Long-term Liabilities  (calculated)8,126,240
+/- 3,960,877
Total Stockholder Equity
Retained Earnings 54,914,183
Total Stockholder Equity (as reported)121,615,310
Total Stockholder Equity (calculated)54,914,183
+/- 66,701,127
Other
Capital Stock7,177,460
Common Stock Shares Outstanding 14,035
Net Debt 22,688,264
Net Invested Capital 164,409,423
Net Working Capital 35,709,121
Property Plant and Equipment Gross 102,408,794



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302013-09-302013-06-302013-03-312012-12-31
> Total Assets 
0
0
0
0
127,967,298
128,880,941
121,815,766
131,226,566
119,208,710
117,933,953
0
123,972,144
127,905,958
113,906,977
120,675,863
125,951,666
133,077,121
137,817,040
147,996,899
150,273,522
157,643,244
156,403,128
159,999,667
158,802,225
169,358,653
176,557,600
175,940,293
183,536,675
176,927,196
188,743,720
197,414,315
197,414,315188,743,720176,927,196183,536,675175,940,293176,557,600169,358,653158,802,225159,999,667156,403,128157,643,244150,273,522147,996,899137,817,040133,077,121125,951,666120,675,863113,906,977127,905,958123,972,1440117,933,953119,208,710131,226,566121,815,766128,880,941127,967,2980000
   > Total Current Assets 
55,242,032
56,332,996
58,653,487
56,954,079
73,512,878
69,378,224
61,147,323
71,242,015
60,130,658
59,007,064
0
56,966,789
66,129,719
66,177,043
70,100,000
74,363,732
68,485,567
69,251,708
75,416,554
71,798,097
76,033,023
81,478,132
87,140,450
89,255,668
102,641,393
101,983,799
107,958,472
112,845,466
98,484,803
102,160,228
99,421,009
99,421,009102,160,22898,484,803112,845,466107,958,472101,983,799102,641,39389,255,66887,140,45081,478,13276,033,02371,798,09775,416,55469,251,70868,485,56774,363,73270,100,00066,177,04366,129,71956,966,789059,007,06460,130,65871,242,01561,147,32369,378,22473,512,87856,954,07958,653,48756,332,99655,242,032
       Cash And Cash Equivalents 
0
0
0
0
10,703,734
8,783,104
4,358,000
14,989,378
6,127,246
7,640,494
0
7,051,347
17,216,594
17,109,643
12,056,201
19,656,503
15,367,779
10,363,899
13,823,971
8,523,738
97
630
390
293
524
17,735,316
980
334
19,201,804
22,601,594
20,105,850
20,105,85022,601,59419,201,80433498017,735,316524293390630978,523,73813,823,97110,363,89915,367,77919,656,50312,056,20117,109,64317,216,5947,051,34707,640,4946,127,24614,989,3784,358,0008,783,10410,703,7340000
       Short-term Investments 
0
0
0
0
812,311
820,000
0
1,536,000
1,634,000
1,005,000
0
0
0
0
0
3,010,000
4,990,727
5,393,114
6,250,618
9,020,402
6,196,592
6,420,622
9,427,347
9,861,857
7,393,777
8,894,765
9,110,200
9,751,970
4,578,273
4,257,394
1,820,000
1,820,0004,257,3944,578,2739,751,9709,110,2008,894,7657,393,7779,861,8579,427,3476,420,6226,196,5929,020,4026,250,6185,393,1144,990,7273,010,000000001,005,0001,634,0001,536,0000820,000812,3110000
       Net Receivables 
45,992,082
46,294,565
47,306,702
46,087,652
46,931,213
45,653,738
42,057,547
41,237,471
41,299,685
38,752,068
0
31,008,373
34,817,287
28,444,174
34,982,225
35,129,334
31,374,920
34,080,025
36,606,298
35,426,346
26,871,176
31,193,054
32,013,291
32,919,213
33,466,167
35,911,394
35,985,711
34,673,035
35,107,543
34,650,463
36,389,449
36,389,44934,650,46335,107,54334,673,03535,985,71135,911,39433,466,16732,919,21332,013,29131,193,05426,871,17635,426,34636,606,29834,080,02531,374,92035,129,33434,982,22528,444,17434,817,28731,008,373038,752,06841,299,68541,237,47142,057,54745,653,73846,931,21346,087,65247,306,70246,294,56545,992,082
       Inventory 
6,452,535
6,706,417
7,205,712
7,244,519
14,901,872
13,756,272
13,048,339
13,312,909
10,878,381
11,163,237
0
12,498,495
12,932,040
14,289,570
15,912,712
14,441,873
14,807,902
17,471,652
17,407,187
17,259,835
20,390,822
23,520,372
23,789,817
24,824,418
30,447,807
28,108,092
32,777,972
32,531,613
32,890,012
33,124,032
33,609,701
33,609,70133,124,03232,890,01232,531,61332,777,97228,108,09230,447,80724,824,41823,789,81723,520,37220,390,82217,259,83517,407,18717,471,65214,807,90214,441,87315,912,71214,289,57012,932,04012,498,495011,163,23710,878,38113,312,90913,048,33913,756,27214,901,8727,244,5197,205,7126,706,4176,452,535
       Other Current Assets 
1,401,144
1,965,899
1,941,771
1,902,520
157,537
329,034
69,798
151,401
186,970
378,063
0
830,000
293,703
33,911,475
1,298,767
1,183,645
1,034,589
1,071,751
478,637
661,055
825,000
820,000
820,000
820,000
820,000
0
820,000
820,000
-2
-1
-1
-1-1-2820,000820,0000820,000820,000820,000820,000825,000661,055478,6371,071,7511,034,5891,183,6451,298,76733,911,475293,703830,0000378,063186,970151,40169,798329,034157,5371,902,5201,941,7711,965,8991,401,144
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,717,261
74,573,801
67,981,821
70,691,209
78,442,393
86,583,492
97,993,306
97,993,30686,583,49278,442,39370,691,20967,981,82174,573,80166,717,261000000000000000000000000
       Property Plant Equipment 
15,318,042
15,248,782
16,050,957
16,405,534
24,430,384
23,808,720
24,017,174
23,361,148
22,807,840
23,225,799
24,819,757
27,664,434
30,876,233
32,462,081
33,954,409
35,294,168
38,570,262
41,649,752
45,933,561
46,457,505
46,294,229
45,605,572
45,348,108
45,918,604
46,977,717
48,333,899
50,197,706
52,668,000
54,312,905
55,889,109
68,689,992
68,689,99255,889,10954,312,90552,668,00050,197,70648,333,89946,977,71745,918,60445,348,10845,605,57246,294,22946,457,50545,933,56141,649,75238,570,26235,294,16833,954,40932,462,08130,876,23327,664,43424,819,75723,225,79922,807,84023,361,14824,017,17423,808,72024,430,38416,405,53416,050,95715,248,78215,318,042
       Long Term Investments 
0
0
0
0
25,776,174
30,440,274
33,087,276
33,089,059
31,849,314
30,866,137
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000030,866,13731,849,31433,089,05933,087,27630,440,27425,776,1740000
       Intangible Assets 
0
0
0
0
863,094
783,705
710,070
606,008
537,860
468,061
0
338,795
268,205
352,644
294,419
317,303
369,697
373,239
461,475
451,403
423,591
396,545
376,210
355,131
336,141
324,642
335,385
555,272
563,834
820,600
1,186,657
1,186,657820,600563,834555,272335,385324,642336,141355,131376,210396,545423,591451,403461,475373,239369,697317,303294,419352,644268,205338,7950468,061537,860606,008710,070783,705863,0940000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
330,416
330,416
810,416
312,416
320,616
390,504
354,303
354,303390,504320,616312,416810,416330,416330,416000000000000000000000000
> Total Liabilities 
0
0
0
0
79,783,451
73,109,826
70,094,974
76,553,638
75,242,974
70,605,175
0
60,528,231
66,839,785
65,000,465
68,292,512
79,176,201
75,945,002
76,954,516
81,638,853
73,791,332
75,177,942
67,017,819
65,845,442
63,386,706
66,399,749
64,906,823
64,931,181
67,820,842
67,571,300
70,783,742
75,799,005
75,799,00570,783,74267,571,30067,820,84264,931,18164,906,82366,399,74963,386,70665,845,44267,017,81975,177,94273,791,33281,638,85376,954,51675,945,00279,176,20168,292,51265,000,46566,839,78560,528,231070,605,17575,242,97476,553,63870,094,97473,109,82679,783,4510000
   > Total Current Liabilities 
46,008,993
47,174,781
48,087,927
49,432,367
57,671,954
47,150,608
50,168,423
55,168,736
58,420,755
54,448,818
0
41,746,458
49,703,466
49,274,116
51,595,124
53,292,979
50,157,386
40,537,916
45,980,643
40,032,826
45,048,609
56,850,814
57,699,558
55,136,836
58,583,501
57,695,709
59,591,686
62,463,465
61,757,919
64,975,215
63,711,888
63,711,88864,975,21561,757,91962,463,46559,591,68657,695,70958,583,50155,136,83657,699,55856,850,81445,048,60940,032,82645,980,64340,537,91650,157,38653,292,97951,595,12449,274,11649,703,46641,746,458054,448,81858,420,75555,168,73650,168,42347,150,60857,671,95449,432,36748,087,92747,174,78146,008,993
       Short-term Debt 
0
0
0
0
36,753,471
2,848,660
8,229,605
9,130,995
13,952,579
13,935,274
0
16,526,304
17,136,684
18,240,579
25,857,219
28,266,125
26,501,426
16,612,369
16,908,220
15,730,613
15,812,430
16,259,746
16,710,711
17,158,133
20,522,535
0
29,432,174
36,327,237
0
0
0
00036,327,23729,432,174020,522,53517,158,13316,710,71116,259,74615,812,43015,730,61316,908,22016,612,36926,501,42628,266,12525,857,21918,240,57917,136,68416,526,304013,935,27413,952,5799,130,9958,229,6052,848,66036,753,4710000
       Short Long Term Debt 
0
0
0
0
36,753,471
2,848,660
8,229,605
9,130,995
13,952,579
13,935,274
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,983,595
32,123,402
31,948,774
36,327,237
35,672,201
34,537,845
35,714,114
35,714,11434,537,84535,672,20136,327,23731,948,77432,123,40233,983,5950000000000000013,935,27413,952,5799,130,9958,229,6052,848,66036,753,4710000
       Accounts payable 
5,626,843
4,970,135
6,951,491
6,591,329
7,717,598
8,989,010
7,903,793
9,190,720
7,863,993
7,544,446
0
5,158,316
5,401,981
6,724,157
6,289,766
6,025,364
4,824,697
6,166,258
6,945,794
8,027,909
0
0
0
0
11,633,427
11,353,947
12,486,330
11,439,491
10,230,291
12,620,415
13,083,623
13,083,62312,620,41510,230,29111,439,49112,486,33011,353,94711,633,42700008,027,9096,945,7946,166,2584,824,6976,025,3646,289,7666,724,1575,401,9815,158,31607,544,4467,863,9939,190,7207,903,7938,989,0107,717,5986,591,3296,951,4914,970,1355,626,843
       Other Current Liabilities 
785,082
1,037,600
939,009
946,544
24,495,724
9,634,938
7,351,640
9,758,895
9,326,821
8,139,604
0
9,119,308
12,449,691
10,690,868
10,779,815
12,700,504
12,411,757
10,502,955
13,662,992
7,697,850
0
0
0
0
-1
0
0
0
0
-1
0
0-10000-100007,697,85013,662,99210,502,95512,411,75712,700,50410,779,81510,690,86812,449,6919,119,30808,139,6049,326,8219,758,8957,351,6409,634,93824,495,724946,544939,0091,037,600785,082
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,816,247
7,211,114
5,339,495
5,357,378
5,813,381
5,808,527
12,087,117
12,087,1175,808,5275,813,3815,357,3785,339,4957,211,1147,816,247000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
11,344,938
8,645,361
8,087,675
7,859,750
10,050,128
9,462,489
19,940,316
19,160,621
16,911,381
15,965,763
4,389,635
2,800,639
2,388,441
2,231,643
0
223,381
242,583
0
0
0
000242,583223,38102,231,6432,388,4412,800,6394,389,63515,965,76316,911,38119,160,62119,940,3169,462,48910,050,1287,859,7508,087,6758,645,36111,344,93800000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-36,753,471
-2,848,660
-8,229,605
-9,130,995
-13,952,579
-13,935,274
0
-16,526,304
-17,136,684
-18,240,579
-25,857,219
-28,266,125
-26,501,426
-16,612,369
-16,908,220
-15,730,613
-15,812,430
-16,259,746
-16,710,711
-17,158,133
-19,869,736
636,274
-28,749,708
-35,618,129
925,586
818,815
1,046,240
1,046,240818,815925,586-35,618,129-28,749,708636,274-19,869,736-17,158,133-16,710,711-16,259,746-15,812,430-15,730,613-16,908,220-16,612,369-26,501,426-28,266,125-25,857,219-18,240,579-17,136,684-16,526,3040-13,935,274-13,952,579-9,130,995-8,229,605-2,848,660-36,753,4710000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
623,214
578,699
534,184
489,669
445,153
400,638
267,092
222,577
178,061
133,546
89,030
44,515
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000044,51589,030133,546178,061222,577267,092400,638445,153489,669534,184578,699623,2140000
> Total Stockholder Equity
0
0
0
0
48,183,847
55,771,115
51,720,792
54,672,928
43,965,737
47,328,778
0
63,443,913
61,066,173
48,906,513
52,383,351
46,775,465
57,132,120
60,862,525
66,358,046
76,482,189
82,465,302
89,385,308
94,154,225
95,415,520
102,958,905
111,650,777
111,009,112
115,715,833
109,355,896
117,959,978
121,615,310
121,615,310117,959,978109,355,896115,715,833111,009,112111,650,777102,958,90595,415,52094,154,22589,385,30882,465,30276,482,18966,358,04660,862,52557,132,12046,775,46552,383,35148,906,51361,066,17363,443,913047,328,77843,965,73754,672,92851,720,79255,771,11548,183,8470000
   Retained Earnings 
9,465,508
9,784,767
8,965,669
10,139,880
-10,702,855
-8,419,715
-15,032,875
-12,077,678
-21,430,242
-16,993,580
-7,468,422
-4,334,853
354,579
3,988,395
7,823,957
6,661,915
-9,814,727
-5,835,349
-911,290
4,222,766
11,724,557
22,214,555
25,488,801
31,418,536
34,997,808
38,018,851
44,446,710
49,425,228
45,500,829
49,314,799
54,914,183
54,914,18349,314,79945,500,82949,425,22844,446,71038,018,85134,997,80831,418,53625,488,80122,214,55511,724,5574,222,766-911,290-5,835,349-9,814,7276,661,9157,823,9573,988,395354,579-4,334,853-7,468,422-16,993,580-21,430,242-12,077,678-15,032,875-8,419,715-10,702,85510,139,8808,965,6699,784,7679,465,508
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
55,675,834
0
55,675,834
55,675,834
0
0
0
00055,675,83455,675,834055,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83455,675,83400000000000
   Treasury Stock0000000000000000000000000000000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue204,222,611
Cost of Revenue-110,239,564
Gross Profit93,983,04693,983,046
 
Operating Income (+$)
Gross Profit93,983,046
Operating Expense-185,413,332
Operating Income18,809,278-91,430,286
 
Operating Expense (+$)
Research Development4,106,345
Selling General Administrative42,514,298
Selling And Marketing Expenses0
Operating Expense185,413,33246,620,643
 
Net Interest Income (+$)
Interest Income363,542
Interest Expense-1,761,528
Other Finance Cost-0
Net Interest Income-1,397,986
 
Pretax Income (+$)
Operating Income18,809,278
Net Interest Income-1,397,986
Other Non-Operating Income Expenses0
Income Before Tax (EBT)20,682,90318,809,278
EBIT - interestExpense = -1,761,528
12,541,894
14,303,422
Interest Expense1,761,528
Earnings Before Interest and Taxes (EBIT)022,444,431
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax20,682,903
Tax Provision-8,141,009
Net Income From Continuing Ops12,541,89412,541,894
Net Income12,541,894
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,397,986
 

Technical Analysis of Daehan New Pharm Co. Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Daehan New Pharm Co. Ltd. The general trend of Daehan New Pharm Co. Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Daehan New Pharm Co. Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Daehan New Pharm Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7,430 < 7,550 < 7,600.

The bearish price targets are: 6,180.

Tweet this
Daehan New Pharm Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Daehan New Pharm Co. Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Daehan New Pharm Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Daehan New Pharm Co. Ltd. The current macd is -115.57998947.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Daehan New Pharm Co. Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Daehan New Pharm Co. Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Daehan New Pharm Co. Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Daehan New Pharm Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartDaehan New Pharm Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Daehan New Pharm Co. Ltd. The current adx is 19.17.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Daehan New Pharm Co. Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Daehan New Pharm Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Daehan New Pharm Co. Ltd. The current sar is 6,359.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Daehan New Pharm Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Daehan New Pharm Co. Ltd. The current rsi is 46.77. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Daehan New Pharm Co. Ltd Daily Relative Strength Index (RSI) ChartDaehan New Pharm Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Daehan New Pharm Co. Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Daehan New Pharm Co. Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Daehan New Pharm Co. Ltd Daily Stochastic Oscillator ChartDaehan New Pharm Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Daehan New Pharm Co. Ltd. The current cci is -2.41448692.

Daehan New Pharm Co. Ltd Daily Commodity Channel Index (CCI) ChartDaehan New Pharm Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Daehan New Pharm Co. Ltd. The current cmo is 0.24068087.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Daehan New Pharm Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartDaehan New Pharm Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Daehan New Pharm Co. Ltd. The current willr is -29.35779817.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Daehan New Pharm Co. Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Daehan New Pharm Co. Ltd Daily Williams %R ChartDaehan New Pharm Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Daehan New Pharm Co. Ltd.

Daehan New Pharm Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Daehan New Pharm Co. Ltd. The current atr is 244.05.

Daehan New Pharm Co. Ltd Daily Average True Range (ATR) ChartDaehan New Pharm Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Daehan New Pharm Co. Ltd. The current obv is 34,831,419.

Daehan New Pharm Co. Ltd Daily On-Balance Volume (OBV) ChartDaehan New Pharm Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Daehan New Pharm Co. Ltd. The current mfi is 41.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Daehan New Pharm Co. Ltd Daily Money Flow Index (MFI) ChartDaehan New Pharm Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Daehan New Pharm Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.

6.3. Candlestick Patterns

Daehan New Pharm Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Daehan New Pharm Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.768
Ma 20Greater thanMa 506,932.500
Ma 50Greater thanMa 1007,369.200
Ma 100Greater thanMa 2008,117.600
OpenGreater thanClose7,010.000
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Daehan New Pharm Co. Ltd with someone you think should read this too:
  • Are you bullish or bearish on Daehan New Pharm Co. Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Daehan New Pharm Co. Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Daehan New Pharm Co. Ltd

I send you an email if I find something interesting about Daehan New Pharm Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Daehan New Pharm Co. Ltd.

Receive notifications about Daehan New Pharm Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.